Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2012, Article ID 735392, 9 pages
http://dx.doi.org/10.1155/2012/735392
Clinical Study

HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era

1Division of Hematology, St. Paul's Hospital and the University of British Columbia, Vancouver, BC, Canada V6T 1Z4
2Division of Hematology, St. Michael's Hospital and the University of Toronto, Toronto, ON, Canada M5S 1A1
3Division of Hematology, Sunnybrook Health Sciences Centre and the University of Toronto, Toronto, ON, Canada M5S 1A1
4Leukemia/BMT Program of British Columbia, BC Cancer Agency, Vancouver, BC, Canada V5Z 1M9
5British Columbia Centre for Excellence in HIV/AIDS (CFE), St. Paul's Hospital and the University of British Columbia, Vancouver, BC, Canada V6T 1Z4
6AIDS Research Program, St. Paul's Hospital and the University of British Columbia, Vancouver, BC, Canada V6T 1Z4

Received 11 June 2011; Accepted 6 September 2011

Academic Editor: Jeremy S. Abramson

Copyright © 2012 J. A. Rodrigo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

J. A. Rodrigo, L. K. Hicks, M. C. Cheung, et al., “HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era,” Advances in Hematology, vol. 2012, Article ID 735392, 9 pages, 2012. https://doi.org/10.1155/2012/735392.